Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson’s disease: a prospective cohort study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson’s disease: a prospective cohort study
Authors
Keywords
-
Journal
BMC Medicine
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-06
DOI
10.1186/s12916-023-03120-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease
- (2023) Katheryn A. Q. Cousins et al. Annals of Clinical and Translational Neurology
- Astrogliosis, neuritic microstructure, and sex effects: GFAP is an indicator of neuritic orientation in women
- (2023) Ashesh A. Thaker et al. BRAIN BEHAVIOR AND IMMUNITY
- Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease
- (2023) Daniele Urso et al. NEUROBIOLOGY OF DISEASE
- Blood GFAP as an emerging biomarker in brain and spinal cord disorders
- (2022) Ahmed Abdelhak et al. Nature Reviews Neurology
- Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years
- (2022) Hannah Stocker et al. Alzheimers & Dementia
- Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson’s disease
- (2022) Eva Gschmack et al. JOURNAL OF NEURAL TRANSMISSION
- Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson’s Disease
- (2022) Lucy L. Gibson et al. Journal of Parkinsons Disease
- Astrocytes in Neurodegeneration: Inspiration From Genetics
- (2022) Jingxuan Huang et al. Frontiers in Neuroscience
- Neocortical Lewy Body Pathology Parallels Parkinson's Dementia, but Not Always
- (2022) W. R. Wayne Martin et al. ANNALS OF NEUROLOGY
- Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease
- (2022) Lucia Batzu et al. npj Parkinsons Disease
- Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
- (2021) Pratishtha Chatterjee et al. Translational Psychiatry
- APOE and MAPT Are Associated With Dementia in Neuropathologically Confirmed Parkinson's Disease
- (2021) Jon-Anders Tunold et al. Frontiers in Neurology
- Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
- (2021) Claudia Cicognola et al. Alzheimers Research & Therapy
- Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease
- (2021) Pratishtha Chatterjee et al. Alzheimers & Dementia
- Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
- (2021) Joana B Pereira et al. BRAIN
- Adenovirus-induced Reactive Astrogliosis Exacerbates the Pathology of Parkinson’s Disease
- (2021) Heeyoung An et al. Experimental Neurobiology
- Longitudinal evolution of non-motor symptoms in early Parkinson’s disease: a 3-year prospective cohort study
- (2021) Ruwei Ou et al. npj Parkinsons Disease
- Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy
- (2021) Lingyu Zhang et al. MOVEMENT DISORDERS
- Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
- (2021) Michael Bartl et al. PLoS One
- Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
- (2021) Andréa L. Benedet et al. JAMA Neurology
- Sex Differences in Behavioral Symptoms and the Levels of Circulating GFAP, Tau, and NfL in Patients With Traumatic Brain Injury
- (2021) Dilorom Sass et al. Frontiers in Pharmacology
- Glial Fibrillary Acidic Protein (GFAP): Neuroinflammation Biomarker in Acute Ischemic Stroke
- (2021) Lisda Amalia Journal of Inflammation Research
- Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia
- (2020) Carolin Heller et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Increased Cerebrospinal Fluid S100B and NSE Reflect Neuronal and Glial Damage in Parkinson’s Disease
- (2020) Ewa Papuć et al. Frontiers in Aging Neuroscience
- Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study
- (2020) Kumar B. Rajan et al. ANNALS OF NEUROLOGY
- Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration
- (2020) Alberto Benussi et al. JOURNAL OF ALZHEIMERS DISEASE
- Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
- (2020) Inge M. W. Verberk et al. Alzheimers Research & Therapy
- Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment
- (2019) Patrick Oeckl et al. JOURNAL OF ALZHEIMERS DISEASE
- Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s disease: an in vivo11C-BU99008 PET study
- (2019) Heather Wilson et al. BRAIN
- Blood NfL
- (2019) Chin-Hsien Lin et al. NEUROLOGY
- Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study
- (2019) John K Yue et al. LANCET NEUROLOGY
- Plasma biomarkers of astrocytic and neuronal dysfunction in early‐ and late‐onset Alzheimer's disease
- (2019) Fanny M. Elahi et al. Alzheimers & Dementia
- GFAP in early multiple sclerosis: A biomarker for inflammation
- (2017) Rebecca Kassubek et al. NEUROSCIENCE LETTERS
- NADPH oxidase-derived H 2 O 2 mediates the regulatory effects of microglia on astrogliosis in experimental models of Parkinson's disease
- (2017) Liyan Hou et al. Redox Biology
- MDS clinical diagnostic criteria for Parkinson's disease
- (2015) Ronald B. Postuma et al. MOVEMENT DISORDERS
- Enteric GFAP expression and phosphorylation in Parkinson's disease
- (2014) Thomas Clairembault et al. JOURNAL OF NEUROCHEMISTRY
- Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease
- (2014) Ricardo Cabezas et al. Frontiers in Cellular Neuroscience
- The Beijing version of the montreal cognitive assessment as a brief screening tool for mild cognitive impairment: a community-based study
- (2012) Jing Yu et al. BMC Psychiatry
- Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients
- (2011) Wen Su et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- The natural history of treated Parkinson's disease in an incident, community based cohort
- (2011) J. R. Evans et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies
- (2010) He-Jin Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Systematic review of levodopa dose equivalency reporting in Parkinson's disease
- (2010) Claire L. Tomlinson et al. MOVEMENT DISORDERS
- CSF amyloid 1-42 predicts cognitive decline in Parkinson disease
- (2010) A. Siderowf et al. NEUROLOGY
- Astrocytic expression of Parkinson's disease-related A53T α-synuclein causes neurodegeneration in mice
- (2010) Xing-Long Gu et al. Molecular Brain
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started